Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bleeding Risks Still A Concern For Patients With Endologix Stent Grafts: FDA Advisory Panel

Company’s latest design fails to convince panel leakage issues have been fixed

Executive Summary

The US agency’s Circulatory System Devices Panel found type III endoleaks are still a problem for abdominal aortic aneurysm patients treated with the newest Endologix stent graft, though for some the benefits still outweigh the risks. The panel advised that all patients, however, should continue getting annual screenings.

You may also be interested in...

FDA Stresses Need For Routine Monitoring Of Endovascular Aortic Repair Patients

A new letter to providers says that to ensure potential adverse events can be identified early, patients should be checked via imaging at 30 days after surgery and at least once a year thereafter.

Find Alternatives To Endologix AFX For Treating Abdominal Aortic Aneurysms, FDA Advises

In its most recent update on the use of Endoglox AFX endovascular grafts, the US FDA is advising physicians use other devices for treating patients with abdominal aortic aneurysms (AAA). AFX still poses bleeding risk.

Bleeding Risk For Endologix AAA Grafts Reconfirmed

Postmarket monitoring continues to show a consistent risk of type III endoleaks in patients with Endologix AFX grafts.


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts